QIAGEN/QGEN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
QGEN
Sector
Healthcare
Trading on
NYSE
Industry
Life Sciences Tools and Services
Headquarters
Venlo, Netherlands
Employees
5,900
Website
www.qiagen.com
QIAGEN Metrics
BasicAdvanced
$9B
Market cap
27.06
P/E ratio
$1.50
EPS
0.42
Beta
-
Dividend rate
Price and volume
Market cap
$9B
Beta
0.42
Financial strength
Current ratio
1.844
Quick ratio
1.224
Long term debt to equity
26.905
Total debt to equity
43.31
Interest coverage (TTM)
8.95%
Management effectiveness
Return on assets (TTM)
4.56%
Return on equity (TTM)
9.41%
Valuation
Price to earnings (TTM)
27.06
Price to revenue (TTM)
4.66
Price to book
2.51
Price to tangible book (TTM)
13.91
Price to free cash flow (TTM)
25.25
Growth
Revenue change (TTM)
-2.99%
Earnings per share change (TTM)
-5.25%
3-year revenue growth
-2.09%
3-year earnings per share growth
-8.69%
What the Analysts think about QIAGEN
Analyst Ratings
Majority rating from 19 analysts.
QIAGEN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$509M
7.00%
Net income
$98M
25.45%
Profit margin
19.17%
17.25%
QIAGEN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.53
$0.52
$0.55
$0.46
-
Expected
$0.52
$0.50
$0.55
$0.44
$0.52
Surprise
1.14%
3.47%
-0.26%
4.83%
-
QIAGEN News
AllArticlesVideos
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
GlobeNewsWire·2 months ago
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
GlobeNewsWire·2 months ago
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $9B as of July 04, 2024.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 27.06 as of July 04, 2024.
Does QIAGEN stock pay dividends?
No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next QIAGEN dividend payment date?
QIAGEN (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell QIAGEN stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.